OBM Attends BioAsia-Taiwan Conference and ACRO Biomedical Announces to Outlicense the Market Rights in 10 ASEAN Countries of its Biocompatible Artificial Cornea, ABCcolla Collagen Ophthalmic Matrix, to Vietnam’s CT Group
23th ~ 27 July 2025

ACRO Biomedical’s Chairman & CEO Dr Hsieh (left) & OBM’s CSO Dr Jiang (right) met for business discussion at 2025 BioAsia Taiwan Conference.

ACRO Biomedical’s Chairman & CEO Dr Hsieh (middle right) & CT Group Chairman Tran Kim Chung (middle left) sign a licensing deal during the 2025 BioAsia Taiwan Conference.

Bio-Asia Taiwan Conference is the Asia’s largest biotech conference and networking event.  OBM again attended this event and its CSO, Dr Jiang, was invited to the section, Australia-Taiwan Clinical Trials Forum on 23^rd July2025 chaired by Australian Office in Taiwan, MTP Connect, BPIPO and Taiwan BioIndustry Organization.  Dr Jiang met with Dr Hsieh, the Chairman & CEO of ACRO Biomedical CO., Inc. (“ACRO”), at the conference and discussed how to further strengthen the partnership between two companies.

During the conference, OBM’s partner, ACRO Biomedical CO., Inc. also held a press conference on 24^th July 2025 and announced that ACRO has signed a licensing deal with Vietnam’s CT Group for the market rights in 10 ASEAN countries for its biocompatible artificial cornea product.  Established in Ho Chi Minh City in 1992, CT Group is one of the Vietnam’s leading technology and innovation corporations which was.  This is a second such agreement followed by the similar one previously signed with OBM for Australian market and other territories.